Evaluation of the Clinical Utility of Circulating Tumor DNA in the Management of Patients With Nonmetastatic Head and Neck Cancer: Protocol for a Prospective Bicentric Study (CIRVAD)
JMIR Research Protocols · 2026-11-05 · 15 · e89973-e89973
DOI: 10.2196/89973 ↗At a glance
Studienprotokoll in JMIR Research Protocols, published online on 2026-11-05. Written by Romina Mastronicola and 7 co-authors. Institution: Head and Neck Department, Institut de Cancérologie de Lorraine, 6 avenue Bourgogne, Vandoeuvre les Nancy, Grand Est, France, 33 782467069. Major MEDLINE topics: Circulating Tumor DNA, Head and Neck Neoplasms, Biomarkers, Tumor, Squamous Cell Carcinoma of Head and Neck. 35 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Human papillomavirus (HPV)–negative head and neck cancers, often linked to tobacco and alcohol exposure, have a poor prognosis and high recurrence rates. Circulating tumor DNA (ctDNA) is a promising biomarker for detecting minimal residual disease and monitoring treatment response. Recent studies show that ctDNA can detect recurrence earlier than clinical or radiological methods. Prospective trials are needed to validate its clinical utility.
Objective
The primary objective is to assess postoperative ctDNA as a predictor of 28-month progression-free survival. Secondary objectives include evaluating ctDNA levels before and after treatment as predictors of recurrence, studying ctDNA dynamics during follow-up in relation to survival, and exploring their association with tumor characteristics and surgical outcomes.
Methods
This prospective, bicentric study evaluates ctDNA in patients undergoing surgery for head and neck squamous cell carcinoma. Plasma ctDNA concentrations will be measured quantitatively in ng/mL before and 1 to 2 weeks after surgery, with or without adjuvant radiotherapy or chemotherapy. Progression-free survival is defined as the time from surgery to disease progression or death, and recurrence-free survival as the time to clinically confirmed recurrence. Overall and disease-specific survival will also be assessed. Changes in ctDNA levels over follow-up and clinical characteristics will be compared between patients with and without progression at 28 months. Absolute and relative variations in ctDNA preoperatively and postoperatively will be described, and surgical quality will be evaluated according to resection margins (R0, R1, R2).
Results
As of August 2026, study preparation, including protocol development and methodological validation, has been completed. The study is currently entering the implementation phase, with regulatory procedures, funding applications, and site initiation activities underway. No participants have been recruited at the time of manuscript submission, as recruitment has not yet begun. Recruitment is expected to start following regulatory approval and funding acquisition. The funding status remains pending as of August 2026, with funding applications underway. Participant recruitment and data collection are projected to take approximately 24 months, followed by a 28-month follow-up period. Data analysis has not yet started and will be conducted after completion of the follow-up period. The first study results are therefore expected to become available after the completion of data collection and follow-up, although a precise publication timeline (season/year) cannot yet be determined.
Conclusions
This study aims to provide key data on the potential of ctDNA to detect early recurrence in HPV-negative cancers and could inform personalized patient monitoring and management.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Head and Neck Department, Institut de Cancérologie de Lorraine, 6 avenue Bourgogne, Vandoeuvre les Nancy, Grand Est, France, 33 782467069.
- Centre de Recherche en Automatique de Nancy, Vandoeuvre les Nancy, Grand Est, France.
Cite
APA
Mastronicola, R., Bresson, M., Gravante, G., Cortese, S., Beulque, E., Chergui, F., Harlé, A., & Dolivet, G. (2026). Evaluation of the Clinical Utility of Circulating Tumor DNA in the Management of Patients With Nonmetastatic Head and Neck Cancer: Protocol for a Prospective Bicentric Study (CIRVAD). JMIR Research Protocols, 15, e89973-e89973. https://doi.org/10.2196/89973
Vancouver
Mastronicola R, Bresson M, Gravante G, Cortese S, Beulque E, Chergui F, et al. Evaluation of the Clinical Utility of Circulating Tumor DNA in the Management of Patients With Nonmetastatic Head and Neck Cancer: Protocol for a Prospective Bicentric Study (CIRVAD). JMIR Research Protocols. 2026;15:e89973-e89973. doi:10.2196/89973
BibTeX
@article{Mastronicola2026,
author = {Mastronicola, Romina and Bresson, Maëlys and Gravante, Giacomo and Cortese, Sophie and Beulque, Emilie and Chergui, Fadila and Harlé, Alexandre and Dolivet, Gilles},
title = {Evaluation of the Clinical Utility of Circulating Tumor DNA in the Management of Patients With Nonmetastatic Head and Neck Cancer: Protocol for a Prospective Bicentric Study (CIRVAD)},
journal = {JMIR Research Protocols},
year = {2026},
volume = {15},
pages = {e89973--e89973},
doi = {10.2196/89973}
}
EUVIMED